{
  "docId": "019de076-906b-74a9-92f8-5c2872231d60",
  "docSlug": "a8776e7183e96a109d1a49143fc2ff88",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 26,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Data presented at AASLD 2023. Shows ELISpot results for T cell responses and HBsAg levels.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-906b-74a9-92f8-5c2872231d60/18",
  "deckHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60",
  "deckJsonHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60.json",
  "deckAnchorHref": "/decks/019de076-906b-74a9-92f8-5c2872231d60#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.7,
        "y": 0.6
      },
      "kind": "callout",
      "text": "Patient 30 (Group A/VTP-300) experienced HBsAg decline and enhanced IFN-y production (via ELISpot) after VTP-300 through Week 48",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87917f97-a205-4993-a659-c2091457ada1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.69,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Immune Profile of Group A/ VTP-300 Subject 30 Through Week 48",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c5ca164-7c42-464f-b41e-a883e49a876c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "HBV-Specific T Cell IFN-y Response Group A (N=4)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7e7b21a-30b6-429b-bac2-1c32dec373f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.32,
        "y": 0.25
      },
      "kind": "chart",
      "text": "HBV-Specific T Cell IFN-y Response Group B (N=3)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f45ef5e1-4d46-46d8-bdd9-f3105e993729",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "Elevations in HBV-specific T cell IFN-y production were observed during imdusiran lead-in and after vaccination for n=7 patients profiled thus far",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3143af4c-5a9e-4956-b395-ef887870fec2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "list",
      "text": "Enhanced HBV-specific T cell responses were observed against HBsAg, PreS1/S2 peptides in VTP-300 treated patients (n=4)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "777b3d8d-b43e-4c97-89d1-a452b7306b2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.83
      },
      "kind": "list",
      "text": "Transient increases in other plasma immune biomarkers were also observed during imdusiran lead-in and vaccination period",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7da5d49-957a-4c2e-ba8a-eb26e4b028e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "AB-729-202: HBV-Specific T Cell Responses and Soluble Immune Biomarkers increased after VTP-300 dosing",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a49cc8f-522d-4d1c-8e31-6c9965f36c84",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 8,
      "beatId": "b0891741-a256-4e4e-a8d2-65a9f9895b7f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Arbutus Biopharma's pipeline and clinical trial results as a solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 18,
      "from": 11,
      "beatId": "bb704643-20a7-459a-9df1-5b5cea9225d9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents clinical trial results and data.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 11,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "9268b1b4-494b-44ee-8454-6a997fc0aa8b",
      "evidence": "The document presents clinical trial results and data.",
      "position": 1,
      "objective": "Can Imdusiran RNAi therapeutic and AB-101 oral PD-L1 inhibitor provide a quick win or a big bet for investors?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}